COVID Impact on China’s NRDL

Published on May 24, 2023

China’s 2022 NRDL could be impacted by the latest omicron wave in a number of ways. Experts Bruce Liu, Ivy Jiang, and Miranda Wang outline the potential challenges ahead to help manufacturers prepare.    

China came out of the COVID-19 pandemic in 2020 and 2021 largely unscathed but was caught by surprise in the latest omicron outbreaks in 2022. The accumulated COVID cases at 1.2 million by mid-May pale in comparison to most other countries, but the lockdowns have been draconian in many cities, with Shanghai among the hardest hit since late March.

Overreacting or not, China will feel the impact in many ways. The National Reimbursement Drug List (NRDL), as the major public funding pathway (updated annually), may face the ripple effects this year.

  1. Potential delay of the NRDL timeline

Each year, the NRDL process normally takes around six months, starting in June, with…